Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amylyx Pharmaceuticals (AMLX) FCF Margin (2021 - 2024)

Amylyx Pharmaceuticals has reported FCF Margin over the past 4 years, most recently at 9281.13% for Q4 2024.

  • Quarterly results put FCF Margin at 9281.13% for Q4 2024, up 926376.0% from a year ago — trailing twelve months through Sep 2025 was 24295.6% (up 2435316.0% YoY), and the annual figure for FY2024 was 192.0%, down 19480.0%.
  • FCF Margin for Q4 2024 was 9281.13% at Amylyx Pharmaceuticals, up from 9988.22% in the prior quarter.
  • Over the last five years, FCF Margin for AMLX hit a ceiling of 9281.13% in Q4 2024 and a floor of 9988.22% in Q3 2024.
  • Median FCF Margin over the past 4 years was 7.45% (2023), compared with a mean of 2066.83%.
  • Peak annual rise in FCF Margin hit 926376bps in 2024, while the deepest fall reached -998284bps in 2024.
  • Amylyx Pharmaceuticals' FCF Margin stood at 7374.74% in 2021, then skyrocketed by 97bps to 189.47% in 2022, then skyrocketed by 109bps to 17.37% in 2023, then soared by 53332bps to 9281.13% in 2024.
  • The last three reported values for FCF Margin were 9281.13% (Q4 2024), 9988.22% (Q3 2024), and 6517.01% (Q2 2024) per Business Quant data.